Cell Cure Neurosciences Ltd.

Cell Cure Neurosciences, a majority-owned (>95%) Israeli subsidiary of Lineage Cell Therapeutics, Inc. a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Our programs are based on as robust proprietary cell-based therapy platform and associated in-house process development and manufacturing capabilities. Our focus is on manufacturing, allogenic, at scale, specialized, terminally differentiated human cells from pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Our presentation will described the approach, technology and understandings carrying out campaigns to support Lineages clinical programs: (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer and (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy.